The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
Some of the key players in the global coagulation testing market include Alere Inc., Hoffmann-La Roche AG, Sysmex Corporation, Abbott, Siemens AG, Axis-Shield Diagnostics Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company and others.
Coagulation tests are performed for diagnosis of the blood clotting system in our body. Different types of coagulation tests are carried out to identify the coagulation process. These tests can be done at hospitals, diagnostic labs, and private clinics and sometimes even at home care facilities. Coagulation tests are generally classified into two major types: global tests and Local or specific tests.Global tests are type of coagulation tests that are performed for diagnosis of the whole blood clotting process. They help in diagnosis of normal state of the blood coagulation and the pathological intensity of the coagulation system. Global tests are generally considered as the first line of diagnostics which provide a complete picture of disorders and malfunctions within the coagulation system. This is useful in identifying the level of problem and to identify the clotting disorder such as hyper or hypo coagulation. Few examples of the global tests are thromboelastography, thrombin generation test, thrombodynamics test.
Local tests are performed to identify the components of the blood coagulation system along with the separate coagulation factors. These are more specific than the global tests as there is a possibility of identification of the disorder location with the accuracy of coagulation factor. Few examples of the local tests are activated partial thromboplastin time and prothrombin time test.
Other examples of the coagulation tests include whole blood clotting time, full blood count and examination and platelet count test. Platelet count test is performed by two major techniques (light scattering, electronic aperture-impedance counting) to distinguish between platelets, leucocytes and erythrocytes. Likewise, other tests include platelet function, platelet aggregation, heparin induced platelet aggregation (diagnosis of heparin-associated thrombocytopenia), Hess test, activated partial thromboplastin time, factor activity assay, thrombin time test, reptilase time test, template bleeding time test, activated coagulation time. According to Universal Biosensors, Prothrombin test helps many of the physicians to administer a safe and effective dose of warfarin to the patients. This test helps determine if the patient is taking in high dose of warfarin which may put them at risk of serious bleeding and if the dose is too little they are at risk of thrombosis. Prothrombin time test allows physicians to adjust the diet and lifestyle changes of the patient according to the warfarin dosage.
View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14168
The increased prevalence of numerous blood clotting disorders such as deep vein thrombosis, hemophilia, thrombophilia, along with growing geriatric population are driving the need for the coagulation testing. Added to the above, the technological advancements in coagulation testing devices such as the modern coagulometers are significantly drive the global demand for coagulation testing market. Hospitals are the largest service providers for the coagulation testing services. Lack of awareness, slow adoption of innovative testing methods especially in the developing countries, high cost of fully automated hemostasis equipment, and risk of side-effects associated with blood testing along with stringent regulations in the approval of coagulation testing devices and assay kits are the major restraints for the growth of coagulation testing devices and the services.
North America and Europe are the major regions for the coagulation testing due to rapid launch of anticoagulants and increased blood clotting disorders. However, Asia and the Latin America regions are identified as the highest scope for coagulation testing owing to increased prevalence of blood disorders, and rising investments by the government to improve healthcare infrastructure these regions. Countries such as China and India are expected to witness considerable growth during the forecast period, owing to growing geriatric population and increasing incidences of blood clotting disorders.